UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 12, 2016

 

 

pSivida Corp.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-51122   26-2774444

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

480 Pleasant Street

Watertown, MA

  02472
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 926-5000

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 12, 2016, pSivida Corp. (the “Company”) eliminated the position of Vice President of Corporate Affairs and General Counsel and therefore Lori Freedman, the Company’s Vice President of Corporate Affairs, General Counsel and Company Secretary, will no longer be employed by the Company effective as of December 26, 2016.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of the Company was held on December 12, 2016. The stockholders elected each of the Company’s nominees for director, approved certain stock option and restricted stock unit grants to the Company’s President and Chief Executive Officer, approved certain stock option grants to the Company’s non-executive directors, approved, on an advisory basis, the Company’s 2016 executive compensation, approved the Company’s 2016 Incentive Plan and ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2017. The proposals below are described in detail in the Company’s definitive proxy statement filed with the SEC on October 26, 2016.

The results are as follows:

 

  1. Election of Directors:

 

     Vote type    Vote Results  

David J. Mazzo, Ph.D.

   For      11,535,068   
   Withheld      5,057,549   
   Non Votes      7,829,221   

Nancy Lurker

   For      13,249,154   
   Withheld      3,343,463   
   Non Votes      7,829,221   

Michael Rogers

   For      11,577,671   
   Withheld      5,014,946   
   Non Votes      7,829,221   

Douglas Godshall

   For      11,576,505   
   Withheld      5,016,112   
   Non Votes      7,829,221   

James Barry, Ph.D.

   For      11,580,505   
   Withheld      5,012,112   
   Non Votes      7,829,221   

Jay Duker, M.D.

   For      11,949,703   
   Withheld      4,642,914   
   Non Votes      7,829,221   

 

  2. Approval of stock option and restricted stock unit grants to Nancy Lurker, President and Chief Executive Officer.

 

Vote type

   Vote Results  

For

     12,460,546   

Against

     3,948,469   

Abstain

     183,602   

Non Votes

     7,829,221   


  3. Approval of stock option grants to the following non-executive directors:

 

     Vote type    Vote Results  

David J. Mazzo, Ph.D.

   For      10,215,707   
   Against      6,060,957   
   Abstain      315,953   
   Non Votes      7,829,221   

Michael Rogers

   For      10,376,196   
   Against      6,048,169   
   Abstain      168,252   
   Non Votes      7,829,221   

Douglas Godshall

   For      10,376,954   
   Against      6,047,494   
   Abstain      168,169   
   Non Votes      7,829,221   

James Barry, Ph.D.

   For      10,379,946   
   Against      6,047,419   
   Abstain      165,252   
   Non Votes      7,829,221   

Jay Duker, M.D.

   For      10,377,804   
   Against      6,049,169   
   Abstain      165,644   
   Non Votes      7,829,221   

 

  4. Approval on an advisory basis of pSivida Corp.’s 2016 executive compensation.

 

Vote type

   Vote Results  

For

     10,136,615   

Against

     6,015,860   

Abstain

     440,142   

Non Votes

     7,829,221   

 

  5. Approval of pSivida Corp. 2016 Incentive Plan

 

Vote type

   Vote Results  

For

     11,244,595   

Against

     5,003,191   

Abstain

     344,831   

Non Votes

     7,829,221   

 

  6. Ratification of the appointment of Deloitte & Touche LLP.

 

Vote type

   Vote Results  

For

     21,068,426   

Against

     3,236,122   

Abstain

     117,290   


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    pSivida Corp.

Date: December 16, 2016

    By:   /s/ Nancy Lurker
    Name:   Nancy Lurker
    Title   President and Chief Executive Officer